(877) 691-7274
​

Sarah Cannon

  • Sarah Cannon
ADVANCING SCIENCE

ADVANCING SCIENCE

At Sarah Cannon, there has been a legacy of devotion to cancer research. Our team of collaborating SCRI sites have enrolled thousands of patients onto clinical trials.

TRANSFORMING CARE

TRANSFORMING CARE

By inhabiting the intersection where cutting-edge research meets compassionate care, we are redefining the standard for quality and excellence in oncology around the world.

POWERED BY PARTNERSHIPS

POWERED BY PARTNERSHIPS

Balancing science, care and commitment, Sarah Cannon is proud to promote partnership with community physicians and academic institutions.

  • Dr. Yardley tells us about her latest research published in the JCO this week: “These remarkable results show that adding entinostat, a class I histone deactelyase inhibitor (HDAC) to standard antiestrogen therapy is a quite effective and well tolerated approach to targeting endocrine resistance pathways in breast cancer,particularly hormone-positive disease.” http://bit.ly/16q8BSk


    Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat
    jco.ascopubs.org
    Purpose Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor–positive (ER+) breast cancer. This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane ver...
    Posted on Fri, May 17 2013

  • Congrats to our very own Dr. Spigel, appointed to @TriStarHealth’s Board of Trustees today. http://bit.ly/11Fq33E
    Posted on Wed, May 15 2013

Ask Sarah - dedicated information service for the oncology community

A dedicated information service for our community of patients and partners.